UPLOAD Filing
Inhibitor Therapeutics, Inc.
Date: July 17, 2025 · CIK: 0001042418 · Accession: 0000000000-25-007569
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-13467
Letter
Re: Inhibitor Therapeutics, Inc. Form 10-K for the Year Ended December 31, 2024 Filed March 28, 2025 File No. 001-13467 Dear James A. McNulty:
July 17, 2025
James A. McNulty Interim Chief Financial Officer Inhibitor Therapeutics, Inc. 3014 W. Palmira Avenue Suite 302 Tampa, FL 33629
We have reviewed your filing and have the following comment.
Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe this comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to this letter, we may have additional comments.
Annual Report on Form 10-K Item 1. Description of Business, page 3
1. We note your disclosure on page 3 that, on December 12, 2023, you entered into an Exclusive License Agreement with Johns Hopkins University. In future filings, please provide further details about the material terms of this agreement including, but not limited to, the aggregate amount that could be owed to Johns Hopkins University pursuant to the agreement, the aggregate milestone amounts to be paid, and the royalty range and term, as applicable. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 or Chris Edwards at 202-551-6761 if you have questions regarding the comment. July 17, 2025 Page 2
Sincerely,
Division of Corporation Finance
Office of Life Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> July 17, 2025 James A. McNulty Interim Chief Financial Officer Inhibitor Therapeutics, Inc. 3014 W. Palmira Avenue Suite 302 Tampa, FL 33629 Re: Inhibitor Therapeutics, Inc. Form 10-K for the Year Ended December 31, 2024 Filed March 28, 2025 File No. 001-13467 Dear James A. McNulty: We have reviewed your filing and have the following comment. Please respond to this letter within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe this comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this letter, we may have additional comments. Annual Report on Form 10-K Item 1. Description of Business, page 3 1. We note your disclosure on page 3 that, on December 12, 2023, you entered into an Exclusive License Agreement with Johns Hopkins University. In future filings, please provide further details about the material terms of this agreement including, but not limited to, the aggregate amount that could be owed to Johns Hopkins University pursuant to the agreement, the aggregate milestone amounts to be paid, and the royalty range and term, as applicable. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 or Chris Edwards at 202-551-6761 if you have questions regarding the comment. July 17, 2025 Page 2 Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>